CAS 1009119-64-5

Daclatasvir

Descripción:

Daclatasvir es un medicamento antiviral que se utiliza principalmente en el tratamiento de infecciones por el virus de la hepatitis C (VHC). Funciona como un agente antiviral de acción directa, específicamente un inhibidor de NS5A, que interfiere con el proceso de replicación viral. Daclatasvir se caracteriza por su alta potencia contra varios genotipos de VHC y a menudo se utiliza en combinación con otros medicamentos antivirales para mejorar la eficacia y reducir el riesgo de resistencia. La sustancia se administra típicamente por vía oral y tiene un perfil farmacocinético favorable, lo que permite una dosificación una vez al día. Su estructura química incluye una disposición compleja de heterociclos, lo que contribuye a su mecanismo de acción y efectividad terapéutica. Daclatasvir generalmente es bien tolerado, con un perfil de efectos secundarios que puede incluir fatiga, dolor de cabeza y náuseas, aunque los efectos adversos graves son raros. Al igual que con cualquier terapia antiviral, es crucial monitorear las interacciones medicamentosas y la adherencia a los regímenes de tratamiento para obtener resultados óptimos en los pacientes que se someten a tratamiento para la hepatitis C.

Fórmula: C₄₀H₅₀N₈O₆

InChI: InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1

Clave InChI: InChIKey=FKRSSPOQAMALKA-CUPIEXAXSA-N

SMILES: C([C@@H](NC(OC)=O)C(C)C)(=O)N1[C@@H](CCC1)C=2NC(=CN2)C3=CC=C(C=C3)C4=CC=C(C=C4)C=5NC(=NC5)[C@H]6N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC6

Sinónimos:

• Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, dimethyl ester
• Carbamic acid, N,N′-[[1,1′-biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C′-dimethyl ester
• Daclatasvir
• Daclavirocyrl
• Daklanork
• Ebp 883
• Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]c arbamate
• dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
• BMS 790052
• Daclatasvir, >=98%
• Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))
• N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester
• Daklinza
• Daclatasvir-d16
• diMethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)
• DiMethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-iMidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-Methyl-1-oxobutane-2, 1-diyl)dicarbaMate (Related Reference)
• Dacaltasvir
• N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester Daclatasvir BMS 790052
• BMS-790052(Daclatasvir)
• Dhaka He Wei
• Daclatasvir/EBP883

Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester

CAS: 1009119-64-5

Fórmula: C₄₀H₅₀N₈O₆

Pureza: 98%

Forma y color: Solid

Peso molecular: 738.8750

Ref: IN-DA00036K

Daclatasvir-d16

CAS: 1009119-64-5

Fórmula: C₄₀H₃₄D₁₆N₈O₆

Forma y color: Yellow Solid

Peso molecular: 754.99

Ref: 4Z-D-145002

Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)Carbamate

CAS: 1009119-64-5

Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)Carbamate

Pureza: 98%

Peso molecular: 738.88g/mol

Ref: 54-OR1026411

Daclatasvir

CAS: 1009119-64-5

Daclatasvir

Pureza: ≥98%

Peso molecular: 738.88g/mol

Ref: 54-BUP14405

Daclatasvir

CAS: 1009119-64-5

Daclatasvir (EBP 883/BMS-790052) is a potent HCV NS5A inhibitor with EC50 9-50 pM across various genotypes. Phase 3.

Fórmula: C₄₀H₅₀N₈O₆

Pureza: 99.81% - 99.99%

Forma y color: Solid

Peso molecular: 738.88

Ref: TM-T6229

Daclatasvir

Producto controlado

CAS: 1009119-64-5

Applications Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
References Gao, M., et al.: Nature, 465(7294), 96 (2010); Bell, T. W., Chem. Med. Chem., 5(10), 1663 (2010);

Fórmula: C₄₀H₅₀N₈O₆

Forma y color: Neat

Peso molecular: 738.88

Ref: TR-D101500

Daclatasvir

CAS: 1009119-64-5

Pureza: 98%

Peso molecular: 738.385

Ref: 10-F979825

Daclatasvir-d6

Producto controlado

CAS: 1009119-64-5

Fórmula: C₄₀D₆H₄₄N₈O₆

Forma y color: Neat

Peso molecular: 744.912

Ref: TR-D101502

Daclatasvir

CAS: 1009119-64-5

Daclatasvir is a direct-acting antiviral agent, which is derived from synthetic chemical sources with a specific mode of action targeting the hepatitis C virus (HCV) replication process. It functions as an inhibitor of the HCV nonstructural protein 5A (NS5A), a vital component necessary for viral RNA replication and virion assembly. By binding to two distinct domains of NS5A, Daclatasvir disrupts its ability to function, thereby effectively halting the replication of the viral genome.

Fórmula: C₄₀H₅₀N₈O₆

Pureza: Min. 95%

Peso molecular: 738.88 g/mol

Ref: 3D-FD158832